Department of Cardiology, First Affiliated Hospital of Chengdu Medical College, Chengdu, Sichuan, China.
Department of Respiratory Diseases, Chengdu Municipal First People's Hospital, Chengdu, Sichuan, China.
Sci Rep. 2017 Jan 10;7:40426. doi: 10.1038/srep40426.
Recent studies have shown platelet to lymphocyte ratio (PLR) to be a potential inflammatory marker in cardiovascular diseases. We performed a meta-analysis to systematically evaluate the prognostic role of PLR in acute coronary syndrome (ACS). A comprehensive literature search up to May 18, 2016 was conducted from PUBMED, EMBASE and Web of science to identify related studies. The risk ratio (RR) with 95% confidence interval (CI) was extracted or calculated for effect estimates. Totally ten studies involving 8932 patients diagnosed with ACS were included in our research. We demonstrated that patients with higher PLR level had significantly higher risk of in-hospital adverse outcomes (RR = 2.24, 95%CI = 1.81-2.77) and long-term adverse outcomes (RR = 2.32, 95%CI = 1.64-3.28). Sensitivity analyses confirmed the stability of our results. We didn't detect significant publication bias by Begg's and Egger's test (p > 0.05). In conclusion, our meta-analysis revealed that PLR is promising biomarker in predicting worse prognosis in ACS patients. The results should be validated by future large-scale, standard investigations.
最近的研究表明血小板与淋巴细胞比值（PLR）是心血管疾病中一种潜在的炎症标志物。我们进行了一项荟萃分析，以系统评估 PLR 在急性冠状动脉综合征（ACS）中的预后作用。从 PUBMED、EMBASE 和 Web of science 进行了全面的文献检索，以确定相关研究。提取或计算效应估计的风险比（RR）及其 95%置信区间（CI）。总共纳入了十项研究，共 8932 例 ACS 患者。我们表明，PLR 水平较高的患者住院不良结局（RR=2.24，95%CI=1.81-2.77）和长期不良结局（RR=2.32，95%CI=1.64-3.28）的风险显著增加。敏感性分析证实了我们结果的稳定性。贝叶斯和伊格检验（p>0.05）未发现显著的发表偏倚。总之，我们的荟萃分析表明 PLR 是预测 ACS 患者预后不良的有前途的生物标志物。需要进一步进行大规模、标准的研究来验证这些结果。
